Sequential

Phase 3Small molecule

PPeking Union Medical College Hospital

Sequential is one of 10 small molecule programs targeting TIA. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TIANot yet recruiting

TIAPhase 3

Not yet recruiting

Competition

Competitive Landscape

14 competitors in TIA

#DrugCompanyPhaseTrials

Taxotere

AAvyxa

Phase 3

1 2

Calquence

AstraZeneca

Phase 2

1 3

Venclexta

AbbVie

Phase 2

1 4

Gazyva

Roche

Phase 2

1 5

Sequential

PPeking Union Medical College Hospital

Phase 3

1 6

Tegafur-Gimeracil-Oteracil

NNational Taiwan University Hospital

Phase 3

1 7

BAY 987519

Bayer

Preclinical

2 8

Apelin

UUniversity of Edinburgh

Preclinical

1 9

Standard SPF 4 Sunscreen

Bayer

Preclinical

2 10

Menopur

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Post-ApprovalNot yet recruiting

TIA

NCT06065267

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer

Completed·NNational Cancer Center, Korea·Phase 2·NCT00532623·82 enrolled

Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer

Completed·PPeking Union Medical College Hospital·Phase 2/3·NCT01413828·201 enrolled

Treatment1 trial

CANHelp Working Group Treatment Trials

Completed·UUniversity of Alberta·Phase 4·NCT01967329·338 enrolled

TIA1 trial

Levofloxacin Concomitant Versus Levofloxacin Sequential

Not yet recruiting·—·Phase 4·NCT06065267·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sequential. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sequential compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sequential. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking Union Medical College Hospital

Sequential

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Breast Cancer2 trials

Treatment1 trial

TIA1 trial

References

Drug Info

Quick Facts

Related News